These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. DprE1--from the discovery to the promising tuberculosis drug target. Mikusová K; Makarov V; Neres J Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764 [TBL] [Abstract][Full Text] [Related]
4. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis. Chikhale RV; Barmade MA; Murumkar PR; Yadav MR J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474 [TBL] [Abstract][Full Text] [Related]
5. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis. Makarov V; Neres J; Hartkoorn RC; Ryabova OB; Kazakova E; Šarkan M; Huszár S; Piton J; Kolly GS; Vocat A; Conroy TM; Mikušová K; Cole ST Antimicrob Agents Chemother; 2015 Aug; 59(8):4446-52. PubMed ID: 25987616 [TBL] [Abstract][Full Text] [Related]
6. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents. Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793 [TBL] [Abstract][Full Text] [Related]
8. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors. Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in the development of DprE1 inhibitors using AI/CADD approaches. Chen K; Xu R; Hu X; Li D; Hou T; Kang Y Drug Discov Today; 2024 Jun; 29(6):103987. PubMed ID: 38670256 [TBL] [Abstract][Full Text] [Related]
10. Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1. Richter A; Rudolph I; Möllmann U; Voigt K; Chung CW; Singh OMP; Rees M; Mendoza-Losana A; Bates R; Ballell L; Batt S; Veerapen N; Fütterer K; Besra G; Imming P; Argyrou A Sci Rep; 2018 Sep; 8(1):13473. PubMed ID: 30194385 [TBL] [Abstract][Full Text] [Related]
11. DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization. Brecik M; Centárová I; Mukherjee R; Kolly GS; Huszár S; Bobovská A; Kilacsková E; Mokošová V; Svetlíková Z; Šarkan M; Neres J; Korduláková J; Cole ST; Mikušová K ACS Chem Biol; 2015 Jul; 10(7):1631-6. PubMed ID: 25906160 [TBL] [Abstract][Full Text] [Related]
12. Virtual Screening of Small Molecular Inhibitors against DprE1. Zhang G; Guo S; Cui H; Qi J Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447 [TBL] [Abstract][Full Text] [Related]
13. Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors. Whitehurst BC; Young RJ; Burley GA; Cacho M; Torres P; Vela-Gonzalez Del Peral L Bioorg Med Chem Lett; 2020 Jun; 30(12):127192. PubMed ID: 32312582 [TBL] [Abstract][Full Text] [Related]